AIBioTech Stock
Contract research organization
Sign up today and learn more about AIBioTech Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About AIBioTech Stock
AIBioTech provides drug discovery and diagnostic development organizations a broad range of world-class laboratory services to bring new products to market. Located in a 32,000 square foot laboratory in Richmond, Virginia, AIBioTech is one of the world's most comprehensive Contract Research Organizations in operation. AIBioTech provides reliable expertise and cutting-edge technologies which are not available from other companies. An expert core laboratory, we provide consultation on experimental design and offer comprehensive services under GLP and non-GLP compliance. These services are offered individually or can be integrated to support product development from discovery-to-market with full Regulatory Support under FDA GLP Guidelines 21 CFR 58. AIBioTech provides the following capabilities to clients: Molecular biology Protein expression & analysis and peptide synthesis & purification Bio-analytical services (CLIA certified) Assay development and validation Microbiology, virology & biosafety testing (BSL3 facilities) Program expertise
Management
Executive VP
Thomas R. Reynolds
Director of Biological Chemistries
Russell L. Wolz
Vice President, DNA Services
Gregory Meyers
Director, QA and Regulatory Compliance
Michelle Lilly
President, CSO
Robert B. Harris
CEO
David Bostwick
Director, Bioorganic Chemistry
Karen Carter
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
